An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

Inclusion Criteria:

- Has stable schizophrenia or schizoaffective disorder

- Has demonstrated ability to tolerate aripiprazole

- Has been on a stable antipsychotic medication regimen without any changes for at least
2 months prior to screening

- Has a body mass index (BMI) of 18.0 to 35.0 kg/m2, inclusive

- Additional criteria may apply

Exclusion Criteria:

- Is pregnant, breastfeeding, or is planning to become pregnant during the study period

- Has received aripiprazole lauroxil or IM depot aripiprazole within 6 months, or other
long-acting, injectable antipsychotic medication within 3 months

- Is a danger to himself/herself at screening or upon admission

- Has a history of or positive test result for human immunodeficiency virus (HIV),
hepatitis B, or hepatitis C

- Has a positive urine drug screen at screening or Day 1

- Additional criteria may apply